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a b s t r a c t 
Cytoplasmic hybrid (cybrid) cell lines can incorporate human subject mitochondria and perpetuate its mi-
tochondrial DNA (mtDNA)-encoded components. Since the nuclear background of different cybrid lines can
be kept constant, this technique allows investigators to study the inﬂuence of mtDNA on cell function. Prior
use of cybrids has elucidated the contribution of mtDNA to a variety of biochemical parameters, including
electron transport chain activities, bioenergetic ﬂuxes, and free radical production. While the interpretation
of data generated from cybrid cell lines has technical limitations, cybrids have contributed valuable insight
into the relationship between mtDNA and phenotype alterations. This review discusses the creation of the
cybrid technique and subsequent data obtained from cybrid applications. 
c © 2014 The Authors. Published by Elsevier B.V.
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 Mitochondria are an essential cellular reticulum driving the
molecular reduction of oxygen into the energy molecule ATP. The
presence of a separate mitochondrial genome was discovered in 1963
[ 1 , 2 ]. The mitochondrial genome is comprised of circular double-
stranded DNA containing 16,569 base pairs. While not all compo-
nents of the electron transport chain (ETC) are encoded by the mito-
chondrial genome, its integrity is vastly important for ETC function.
The mitochondrial genome encodes 11 components of the ETC and
two subunits of ATP synthase ( Fig. 1 ). In addition, the mitochondrial
genome contains 24 tRNA / rRNA genes, which are required for trans-
lation of mitochondrial proteins ( Fig. 1 ). The importance of mtDNA
is highlighted by ﬁndings of mtDNA mutations and mitochondrial
dysfunction in diseases associated with aging [ 3 –5 ]. 
The cybrid technique 
Rho zero cells 
To facilitate cybrid generation, cells devoid of mtDNA are com-
monly utilized. These cells are termed ρ0 cell lines because prior to
identiﬁcation of the mitochondrial genome the DNA found in the cyto-
plasm of cells was termed “ρ-DNA” [ 6 ]. The ability to deplete mtDNA
was ﬁrst discovered in yeast models where natural mtDNA depletion
occurred under conditions in which glycolysis was favored over mito-
chondrial respiration. This led to artiﬁcial techniques to deplete cells* Correspondence to: Department of Neurology, 3901 Rainbow Blvd MS 2012, Uni- 
versity of Kansas Medical Center, Kansas City, KS 66160, USA. 
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http://dx.doi.org/10.1016/j.redox.2014.03.006 of mtDNA, the oldest of which is the use of the DNA-intercalating
agent ethidium bromide (EtBr). EtBr, a positively charged aromatic
compound, is attracted to negatively charged DNA molecules located
within negatively charged mitochondrial matrices. Intercalation of
EtBr into DNA results in the failure of DNA replication by DNA poly-
merase. The use of EtBr in yeast cells culminated in partial and com-
plete mtDNA depletion [ 7 –9 ]. 
When extended to vertebrate cells, the development of mtDNA de-
pletion protocols proved more difﬁcult. In one reported early attempt,
while treatment with EtBr did result in almost complete depletion of
mtDNA from the VA 2 B human cell line, the high concentrations of
EtBr that were used were toxic. Additionally, immediately following
removal of EtBr, mtDNA was replenished [ 10 ]. 
The ﬁrst successful vertebrate ρ0 cell lines were made in chicken
embryo ﬁbroblast cells using EtBr. The investigators determined the
resulting cells were auxotrophic for the pyrimidine nucleoside uri-
dine [ 11 ]. The basis for this can be explained by the function of di-
hydroorotate dehydrogenase. This mitochondrial enzyme is required
for the synthesis of pyrimidines and relies upon the ETC to func-
tion [ 12 ]. Therefore, depletion of mtDNA and subsequent ETC fail-
ure will disrupt pyrimidine synthesis. Supplementing mtDNA- de-
pleted cells with uridine bypasses the ETC-dependent, dihydroorotate
dehydrogenase-catalyzed step in the pyrimidine synthesis pathway.
An avian ρ0 cell line was subsequently generated using the same
protocol, reducing mtDNA copy number from 300 per cell to unde-
tectable levels [ 13 ]. It is important to emphasize, though, that ρ0 cells
retain mitochondria [ 14 ]. These mitochondria are not respiration-
competent, but they do retain a membrane potential, presumably
by operating their ATP synthase in reverse. Although their structure open access article under the CC BY-NC-ND license ( http: // creativecommons.org / 
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Fig. 1. The mitochondrial genome. This ﬁgure depicts the circular mitochondrial genome. Structural genes are shown in yellow. rRNA genes are shown in blue, while tRNA genes 
are shown in black. The regulatory region, D-loop, is shown in red. CO = cytochrome oxidase, ND = NADH dehydrogenase. 
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Table 1 
Reported ρ0 cell lines. 
ρ0 cell line Reference 
143B osteosarcoma [ 16 ] 
HeLa cervical carcinoma [ 18 ] 
A549 lung carcinoma [ 19 ] 
Lymphoblastoid, Wal2A [ 20 , 21 ] 
SH-SY5Y neuroblastoma [ 22 ] 
NT2 teratocarcinoma [ 23 , 24 ] 
U251 glioma [ 25 ] 
Fibroblast / transformed ﬁbroblast [ 26 ] 
LL / 2-m21 mouse [ 27 ] 
T-cell lymphoblastic leukemia, 
molt-4 
[ 28 ] s altered they undergo proliferation and receive nuclear-encoded 
itochondrial proteins. These respiration-incompetent mitochondria 
ave been colloquially referred to by some authors as “mitoids” [ 15 ]. 
In 1989, the human osteosarcoma 143B cell line was depleted of 
tDNA. The ρ0 clones (143B101 and 143B106) were auxotrophic 
or both uridine and pyruvate [ 16 ]. The necessity for pyruvate sup- 
lementation was hypothesized to be required for the maintenance 
f cellular redox status [ 17 ]. Cells devoid of mtDNA rely upon gly- 
olysis for ATP production. Under physiological conditions, glycoly- 
is increases NADH levels, while mitochondrial respiration produces 
AD + . Therefore, the absence of mitochondrial respiration signiﬁ- 
antly increases the NADH: NAD + ratio, interfering with glycolytic 
apacity. Supplementation with pyruvate leads to the formation of 
actate, which generates NAD + , thus allowing glycolytic function and 
TP production. Additional cell lines have been depleted of mtDNA 
ver the course of time. Table 1 provides a list of currently reported 
0 cell lines. 
To understand the mechanisms of mtDNA depletion, it is impor- 
ant to understand that the depletion of mtDNA occurs in two steps. 
irst is the cessation of mtDNA replication. This step does not elimi- 
ate existing mtDNA molecules, but terminates their ability to repli- 
ate the mtDNA. As the cells divide, the mtDNA is divided among the 
ew cells, leading to continuous dilution of the mtDNA pool. This cre- 
tes a cell population in which some cells contain mtDNA while other cells lack the mtDNA—and are now “ρ0”. The second step begins at 
this point, in which ρ0 cells are isolated and expanded, or mtDNA 
depletion continues until all mtDNA is degraded. 
Further development of techniques to deplete cells of mtDNA have 
moved away from the use of EtBr. The mitochondrial DNA polymerase 
γ inhibitor, ditercalinium, or expression of a dominant negative mito- 
chondrial DNA polymerase γ construct have been used successfully to 
create ρ0 cell lines [ 29 , 30 ]. Exposure to dideoxynucleoside analogues, 
which interfere with mtDNA replication, leads to mtDNA depletion 
myopathy and is another technique for creating ρ0 cell lines [ 31 , 32 ]. 
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 Rhodamine 6-G, ﬁrst noted for its ability to interfere with mitochon-
drial ETC function, is an additional tool for the generation ρ0 cell
lines [ 33 –35 ]. More recent techniques to deplete mtDNA have used
the expression of mitochondrial targeted EcoRI, which is the focus of
a biotech company, Rho Zero Technologies [ 36 , 37 ]. 
The generation of ρ0 cell lines requires techniques to verify de-
pletion of the mtDNA. Several applications have been reported de-
scribing how to document ρ0 status. Techniques include southern
blotting, PCR of mtDNA, competitive PCR to ratio mtDNA and nuclear
pseudogenes, measurement of oxygen consumption and cytochrome
c oxidase activity, pico green staining, and uridine / pyruvate auxotro-
phy [ 18 , 19 , 21 –26 ]. The majority of these techniques depend upon the
demonstration of a negative result. Most of these techniques, there-
fore, are limited by the sensitivity of the mtDNA detection protocol.
Testing for uridine / pyruvate auxotrophy, however, is a practical ap-
proach which does not rely upon a negative result. A more recently
developed technique, competitive PCR, is more labor intensive but
also does not rely upon demonstration of a negative result. The com-
petitive PCR approach provides a means to statistically analyze the
probability of mtDNA depletion and that ρ0 status has been achieved
[ 25 ]. 
mtDNA Transfer 
During the development of mtDNA depletion techniques, methods
for transferring mtDNA into cells were simultaneously being estab-
lished. The ﬁrst attempt, in 1972, led to the creation of a heterokaryon
hybrid cell, which used the Sendai virus to fuse cells together [ 38 ].
Two years later, a separate technique was carried out using mixtures
of nucleated cells and cytoplasts (non-nucleated cells) [ 39 ]. Bunn et
al. called the resulting cells “cybrid” cells, distinguishing them from
the term “hybrid”, which implies the mixture of two nucleated cells. 
The cybrid technique was ﬁrst utilized in 1975, to determine if
chloramphenicol resistance was mediated by the cytoplasm in a hu-
man cell line [ 40 ]. Cytoplasts were generated from a chloramphenicol
resistant HeLa cell line fused with a chloramphenicol susceptible HeLa
cell line that was also thymidine kinase negative (TK −). The difference
in TK content allowed for a selection process to eliminate intact chlo-
ramphenicol resistant cells which may have failed the enucleation
procedure. This is important because both HeLa cell lines perpetuate,
and contamination with intact chloramphenicol-resistant cells could
lead to confounded results. It was ultimately concluded that the cy-
brid cells were chloramphenicol resistant, and that this characteristic
was dependent upon the cytoplasm of the cell. Fig. 2 depicts this type
of cybrid generation strategy, in which mitochondria are transferred
from one nuclear partner to another, even though the recipient nu-
cleated cell is not a ρ0 cell. 
A separate cybrid technique—ﬁrst reported in 1989—fuses enucle-
ated cytoplasts with ρ0 cells. Cytoplasmic transfer to the ρ0 cell line
was mediated through the use of polyethylene glycol, as well as di-
rect injection of cytoplast mitochondria [ 16 ]. Repopulation of the ρ0
cell line with mtDNA was depicted through loss of uridine / pyruvate
auxotrophy and restoration of oxidative phosphorylation biochemi-
cal measurements. Fig. 2 shows a schematic for this cybrid generation
strategy. To further simplify the cybrid technique, Chomyn et al. [ 41 ]
used a procedure in which platelets were employed as cytoplasts.
Platelets do not contain a nucleus, therefore pre-fusion enucleation
of the cytoplasmic donor cell is not required. 
Two separate studies subsequently reported that synaptosomes
from brain tissue could also serve as cytoplasts for mtDNA fusion
[ 42 , 43 ]. However, the use of synaptosomes has overall proved chal-
lenging, because the efﬁciency of mtDNA transfer is low when fresh
brain extracts are used from mice and dismal when post-mortem
human brain tissue are used [ 44 ]. The use of cybrids to study mitochondrial genetics and mtDNA-nuclear 
DNA compatibility 
Early cybrid studies used ﬁbroblast mitochondria which contained
mtDNA that harbored known pathogenic mutations. The major goal
of these initial studies was to understand the pathological mecha-
nisms underlying diseases associated with mtDNA mutations. To bet-
ter understand the power of cybrids for this application, it is worth
reviewing some basic mitochondrial genetic tenets. 
Cells contain numerous copies of mtDNA. Homoplasmy deﬁnes a
state in which the mtDNA sequence of different mtDNA molecules
within a cell is always the same. Homoplasmy is the mitochondrial
equivalent of nuclear homozygosity. However, it is reasonably com-
mon for mtDNA molecules within a cell, tissue, or organism to exhibit
sequence heterogeneity. This state is called heteroplasmy. Hetero-
plasmy can be considered to loosely correspond to nuclear heterozy-
gosity, but in reality it is far more complex. Because mtDNA is not
a binary system like nuclear DNA, different ratios of wild-type and
mutant mtDNA molecules can reside within a single mitochondrion
or a single cell. Therefore, a heteroplasmic mutation can be present
in varying degrees, and in either low or high abundance. 
Threshold refers to the mtDNA mutational load that is required
within a cell to cause a biochemical or phenotypic consequence. It
is reasonable to hypothesize that the more pathogenic the mtDNA
mutation, the lower abundance is necessary to reach a threshold that
changes mitochondrial and, therefore, cell physiology. A schematic
depicting the use of cybrids to study mtDNA heteroplasmy is shown
in Fig. 3 A. 
The A3243G mtDNA mutation associated with the mitochondrial
encephalopathy, lactic acidosis, and stroke-like episodes syndrome
(MELAS) was studied using the cybrid model. mtDNA nucleotide 3243
is located within one of the two mtDNA genes that encodes a leucine
tRNA (tRNA Leu UUR ). This mutation does not produce an aberrant
protein because the gene product is synthetic and not structural in
nature. MELAS cybrids were made using osteosarcoma ρ0 cell lines,
and found that a high mutational burden of 85% was required be-
fore phenotypic consequences were observed [ 45 –48 ]. The mecha-
nism leading to biochemical changes with this mtDNA mutation is
related to translation deﬁciency of mtDNA-encoded structural pro-
teins [ 45 , 49 ]. Following these initial studies, it became apparent that
the nuclear background of the ρ0 cell used inﬂuenced the mitochon-
drial genotype–phenotype relationship. In the osteosarcoma MELAS
cybrid model, a 90% mutational burden resulted in a 30% decrease in
cytochrome oxidase activity, while an A549 lung carcinoma MELAS
cybrid model required only a 55% mutational burden to observe a
50% reduction in cytochrome oxidase activity [ 50 ]. Both cybrid mod-
els required substantial mtDNA mutation load to alter biochemical
endpoints compared to those required in human muscle [ 51 , 52 ]. Fi-
nally, nuclear differences in mutational drift were observed over time.
For example, one nuclear background led to drift away from the mu-
tant mtDNA, while a separate nuclear background led to drift toward
the mutant mtDNA [ 50 , 53 , 54 ]. 
Other cybrid studies have examined mtDNA transfer from people
with Leber ’ s hereditary optic neuropathy (LHON). LHON is associ-
ated with mutations in mtDNA structural genes, unlike the synthetic
gene mutations observed in MELAS. No single mutation leads to the
LHON phenotype, as several distinct mutations have been reported.
All mutations that lead to the LHON phenotype are found in structural
genes, and mutations within the NADH dehydrogenase (ND) genes,
which encode for Complex I subunits, are most common. The most
frequently reported mutation is G11778A, which resides in the ND4
gene. LHON cybrid data suggests that biochemical consequences de-
pend upon the mutation and nuclear background of the ρ0 cell line
that is utilized. For example, LHON mutations that show no Com-
plex I defects in one nuclear background can show Complex I defects
in a separate nuclear background. The only consistent parameters
622 H.M. Wilkins et al. / Redox Biology 2 (2014) 619–631 
Fig. 2. Cybrid generation techniques. Cybrids are produced by combining cytoplasm from nucleated cells with non-nucleated cells or cytoplasts. The nucleated cell can be unaltered, 
or could have undergone depletion of endogenous mtDNA before cytoplasmic mixing. In either case, the goal is to populate the nucleated cell with mtDNA from the non-nucleated 
cell. 
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 reduction in Complex I-dependent ATP synthesis. All phenotypic 
ifferences required a high mutational load, which is consistent with 
hat is observed in the clinical setting, where people afﬂicted with 
HON are homoplasmic or the mtDNA mutation is present at a high 
opy number [ 21 , 55 –61 ]. 
LHON cybrid studies using an osteosarcoma nuclear background 
ore recently reported that mitochondrial haplogroup status is also 
n important determining factor for the pathogenic potential of dif- 
erent LHON mutations [ 62 –64 ]. Mitochondrial haplogroups are de- 
ermined by ancestral hereditary. Mitochondrial haplogroup J and 
k are found at higher levels in persons afﬂicted with LHON, how- 
ver haplogroup H is under represented in the incidence of LHON. 
ybrids from different human mitochondrial haplogroups were gen- 
rated using platelets fused on the osteosarcoma nuclear background. 
aplogroup Uk and J have decreased mtDNA, mitochondrial RNA and 
itochondrial protein translation products compared to haplogroup 
. In addition, haplogroups Uk and J have lower oxygen consump- 
ion, ATP production, and mitochondrial membrane potential when 
ompared to haplogroup H. In particular, LHON osteosarcoma cybrids 
ad accumulations of low-molecular weight sub-complexes, partic- 
larly from Complex I structural proteins. However, polymorphisms in mtDNA, or speciﬁc mitochondrial haplogroups, inﬂuenced the as- 
sembly rates and stability of Complex I, III, and IV [ 62 ]. Overall, cybrid 
studies have contributed and will continue to be important to the 
understanding of how haplogroups inﬂuence multifactorial diseases, 
such as LHON. 
Further LHON cybrid studies used the teratocarcinoma NT2 cell 
line as a nuclear background donor [ 35 ]. From a modeling perspec- 
tive, the use of this ρ0 cell line to generate LHON cybrids may be 
argued to be more closely related to the disease itself, since NT2 cells 
display “neuronal-like” features and can be differentiated into neu- 
rons using retinoic acid [ 65 ]. It was found that undifferentiated LHON 
NT2 cybrids did not have altered biochemical parameters, but upon 
differentiation parametric differences could be observed. The pheno- 
typic differences observed in the LHON NT2 cybrids were diminished 
efﬁciency in the differentiation protocol and production of higher lev- 
els of reactive oxygen species (ROS) when compared to control NT2 
cybrids. An additional study using LHON NT2 cybrids depicted these 
cells were more sensitive to H 2 O 2 , displayed no change in superoxide 
dismutase (SOD) activity, but had decreased glutathione (GSH) lev- 
els [ 66 ]. However, these data again depict the importance of nuclear 
background, as similar LHON cybrids generated on an osteosarcoma 
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Fig. 3. Applications of the cybrid model. Cybrids can be used to (A) evaluate heteroplasmy-threshold corrections. It is unknown whether heteroplasmic mtDNA changes are found 
at the cellular level or the level of each mitochondrion. Such that, a single mitochondria could contain both wild-type and mutated mtDNA, or a cell could contain a population of 
mitochondria which have wild-type mtDNA and a population of mitochondria which have mutant mtDNA. Beyond that, a particular cell could contain all wild-type mtDNA, while 
a separate cell contains all mutant mtDNA. (B) Test mtDNA–nuclear DNA compatibility and (C) screen for mtDNA-determined functional differences between cell lines containing 
mtDNA from different sources. 
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uackground showed increased ROS production, decreased SOD activ- 
ty, but no reduction in GSH levels [ 67 ]. 
Other diseases with known mtDNA mutations have been stud- 
ed using the cybrid technique. These include myoclonic epilepsy 
nd ragged red ﬁber disease (MERRF), Leigh ’ s disease due to 
tDNA mutation / neuropathy, ataxia, retinitis pigmentosa (NARP), 
nd Kearns–Sayre Syndrome [ 41 , 68 –73 ]. Kearns–Sayre Syndrome in- 
olves deletions of mtDNA, and cybrid work has resulted in notable 
ndings [ 72 ]. One important ﬁnding is that large mtDNA deletions 
esult in mitochondrial respiration failure, but mtDNA duplications 
o not. In addition, osteosarcoma cybrid cell lines, it appears, prefer 
o maintain a stable mtDNA total amount, as opposed to maintain- 
ng a constant mtDNA copy number. When osteosarcoma cells are 
redominately populated with mtDNA that contains large deletions, 
tDNA copy number increases to compensate, which ultimately re- 
ults in an amount of total mtDNA that is equivalent, in mass to that 
f cells without large deletions. 
Studies examining mtDNA-nuclear DNA compatibility have also 
tilized the cybrid approach. These studies generated xenomitochon- 
rial cell lines, where cytoplasts from primate ﬁbroblasts were fused 
ith a human osteosarcoma ρ0 cell line [ 74 , 75 ]. This mtDNA trans- 
er gave rise to viable cybrid cell lines when the transferred mtDNA 
as derived from common chimpanzee, pigmy chimpanzee or go- 
illa ﬁbroblasts. Orangutan, Old-world monkey, New-world monkey, 
nd Lemur mtDNA were not compatible with the human osteosar- 
oma nuclear background, as no viable cybrid cells resulted. Cybrids 
xpressing common chimpanzee mtDNA displayed a 20% lower oxy- 
en consumption rate, while cybrids expressing pigmy chimpanzee 
tDNA had 34% reduced oxygen consumption, and cybrids express- 
ng gorilla mtDNA had 27% less oxygen consumption. No deﬁcits were 
ound for any of the xenomitochondrial cybrids with respect to Com- 
lex II, III, or IV activities. However, cybrids expressing common chim- 
anzee mtDNA showed a 41% reduction in Complex I activity, while 
ybrids expressing pigmy chimpanzee mtDNA had a 43% reduction 
n Complex I activity, and cybrids expressing gorilla mtDNA had 45% 
ower complex I activity. These are ﬁndings of interest because there 
re 159 amino acid differences between human and common chim- 
anzee mtDNA coding, 155 amino acid differences between human 
nd pigmy chimpanzee mtDNA coding, 195 amino acid differences 
etween human and gorilla mtDNA coding, and 411 amino acid dif- 
erences between human and orangutan mtDNA coding. The conclu- 
ions drawn from this study are that primates which evolved longer 
han approx. 18 million years ago cannot function to replace human 
tDNA. Fig. 3 B shows a schematic of this cybrid application. 
he use of cybrids as a Model for Mitochondriopathy-Associated 
poradic diseases 
Cybrid models have also been applied to test mitochondrial and 
ell physiology alterations arising from un-sequenced mtDNA. Here, 
tDNA is transferred from an individual with a particular condition 
r disease, as shown in Fig. 3 C. The resulting cybrid cell lines are ex- 
anded and used to measure biochemical and molecular endpoints, 
nd compared to cybrid cell lines derived from control patients. Due 
o the nuclear background and environment (i.e. cell culture param- 
ters) being constant, the differences observed in measured indices 
re assumed to reﬂect differences in mtDNA [ 76 ]. However, several 
riticisms of this cybrid application have arisen. 
Most controversy surrounding this cybrid application is due to 
ts assumption that the functional differences in cybrid cell lines are 
ue to differences in mtDNA. Because the cybrid technique does not 
olely transfer isolated mtDNA, this assumption of differences being 
olely due to mtDNA is a leap of faith in some aspects. At a mini- 
um, whole mitochondrial transfer occurs from donor platelets or 
ytoplasts. However, during the time it takes to select for cells repop- 
lated with mtDNA, the cybrids pass through multiple cell division cycles, during which any possible non-perpetuating materials that 
were transferred are repeatedly diluted. For a case in which a dou- 
bling time of 24 h is expected, several weeks of cybrid selection and 
expansion would result in over a billion-fold dilution of any non- 
perpetuating material. Therefore, theoretically the only transferred 
cytoplast or platelet component that is self-perpetuating is mtDNA. 
Another common criticism of this cybrid application is veriﬁcation 
of results. Presumably, if a goal of using cybrid models is to implicate 
the presence of mtDNA differences in structural, synthetic, or reg- 
ulatory genes (such as the D-loop), then actual nucleotide changes 
should be demonstrable. While this notion is conceptually correct, 
it is important to note that correlating speciﬁc nucleotide devia- 
tions to speciﬁc phenotype changes is challenging because mtDNA 
sequences between individuals tend to vary substantially. The ques- 
tion, therefore, is often not whether a particular mtDNA donor has 
sequence variations, but whether deviations that can be detected are 
functionally relevant. This differs from studies of Mendelian diseases, 
in which the functional relevance of a particular DNA sequence is 
generally resolved by tracking the suspect variation through family 
pedigrees; addressing whether the sequence variation is exclusive 
to a particular phenotype is relatively straightforward. However, the 
mitochondrial genome is not inherited through Mendelian patterns. 
mtDNA is normally inherited maternally, although rare cases of mu- 
tant mtDNA inheritance via sperm have been reported [ 77 ]. While 
some mtDNA-associated diseases do show recognizable maternal in- 
heritance patterns [ 78 ], it is increasingly suspected that a majority of 
the time mtDNA inﬂuences disease risk or development in a primar- 
ily sporadic or pseudo-sporadic fashion [ 79 , 80 ]. Overall, this limits 
the ability to associate mtDNA sequence variations with a particular 
disease state. 
When it comes to establishing mtDNA sequence-phenotype as- 
sociations, though, the greatest limiting factor may turn out to be 
mtDNA heteroplasmy. The traditional Sanger-based sequencing ap- 
proach is not designed to detect low abundance heteroplasmic muta- 
tions; if the mutational load is less than 20–30%, the ability to detect 
the mtDNA change is unreliable [ 81 , 82 ]. Further, recent data indicate 
mtDNA contains large numbers of low percentage, “microheteroplas- 
mic” sequence variations [ 3 , 83 –86 ]. It has been postulated that these 
microheteroplasmic variations are present at 1–2% abundance [ 87 ]. 
Microheteroplasmic variations within tissue also exist, and the pres- 
ence of “compound microheteroplasmy”, once postulated [ 88 ], has 
since been veriﬁed using next generation sequencing [ 86 ]. 
In addition to questions over the functional signiﬁcance of mtDNA 
sequence deviations, the origin of especially heteroplasmic sequenc- 
ing deviations may be difﬁcult to prove. mtDNA sequence mutations 
that are anatomically limited within an individual may arise from 
inherited mutations via mitotic segregation (the mtDNA correlate 
of mosaicism), or represent somatically acquired mutations. There- 
fore, we will consider cybrid studies that depict biochemical differ- 
ences between mtDNA donors as simply supporting the notion that 
functionally relevant mtDNA differences exist between the mtDNA 
donors, without concluding whether those differences are inherited 
or acquired. 
Cybrid models have been used to screen for mtDNA aberrancy in 
several neurodegenerative diseases, particularly Parkinson ’ s disease 
(PD) and Alzheimer ’ s disease (AD). When the ﬁrst cybrid studies of PD 
and AD were performed, it was already known that people afﬂicted 
with these diseases had speciﬁc ETC deﬁcits [ 89 , 90 ]. Many argue that 
mitochondrial defects are secondary pathologies and / or irrelevant to 
the phenotype of these diseases. However, the fact remains that mi- 
tochondrial function within these diseases is not normal. This has led 
to these diseases being classiﬁed as “neurodegenerative mitochon- 
driopathies” [ 91 ]. 
It has been repeatedly shown that Complex IV activity is reduced 
in AD subjects, and that Complex I activity is reduced in PD patients 
[ 76 , 92 –95 ]. These deﬁcits are not only found in the brains of those 
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 afﬂicted with AD and PD, but also systemically in platelet mitochon-
dria. The sporadic and systemic nature of these diseases makes the
cybrid model a good application for study [ 96 ]. The cybrid technique
seemed a reasonable approach to address the question of whether
mtDNA accounted for at least part of the lesions observed in AD and
PD. 
The ﬁrst PD cybrid study used the human SH-SY5Y neuroblas-
toma (“neuron-like”) ρ0 cell line as the nuclear background. Platelets
from 24 PD subjects and 28 age-matched control subjects pro-
vided mtDNA [ 15 ]. ETC Vmax measurements were taken from post-
nuclear mitochondria enriched fractions from each cell line, 52 in
total. Absolute Vmax levels were corrected for total protein content
of mitochondrial-enriched fractions. The Complex I Vmax was de-
creased by 20% in the PD group compared to the control group. No
difference was observed in Complex IV Vmax measurements between
groups. This indicated mitochondrial repopulation was equivalent be-
tween PD and control groups. This study supports the notion that
Complex I deﬁcits observed in sporadic PD patients are at least par-
tially determined by mtDNA. 
Deﬁcits in Complex I activity in PD cybrids compared to control
cybrids were veriﬁed by four independent studies. One study used
the SH-SY5Y ρ0 cell line as the nuclear background, while the other
studies used the A549 lung carcinoma ρ0 cell line or the NT2 terato-
carcinoma cell line, respectively [ 97 –100 ]. A separate study was com-
pleted in which cybrids were generated from a large family in which
multiple members had PD [ 78 ]. The pattern of PD inheritance of this
family was consistent with maternal transmission. Cybrids generated
from family members afﬂicted with PD had decreased Complex I ac-
tivity when compared to cybrids generated from family members
not afﬂicted with PD. Furthermore, family members who had strict
maternal inheritance, but were younger than the age of onset for
PD within this family, had lower mean Complex I activity than their
paternally-descended cousins. In contrast, cybrids containing platelet
mtDNA from members of the Contursi kindred did not show reduced
Complex I activity [ 101 ]. In the Contursi kindred PD arises due to an
autosomal dominant mutation in the α-synuclein gene. This inheri-
tance pattern implies that the genetic etiology differs between those
with nuclear gene mutations and those with the more common spo-
radic form or forms. mtDNA would be more likely to contribute to
risk or onset in the sporadic cases. 
PD cybrids have been analyzed for a variety of biochemical and
molecular parameters. Increased ROS production and upregulation
of antioxidant enzyme activity have been observed [ 15 , 99 , 102 ]. PD
cybrids are more sensitive to H 2 O 2 exposure and have decreased
GSH content [ 103 ]. Bcl-2 and Bcl-XL levels are upregulated, NFkB is
activated, there is enhanced p38 and JNK activity, and PARP cleav-
age is increased [ 100 , 104 –106 ]. These ﬁndings are consistent with
increased oxidative stress, as signaling pathways involved in both
cell death and survival stress responses are enhanced in PD cybrids.
Furthermore, mitochondrial calcium levels are reduced [ 107 ]. Maxi-
mum respiration capacity was lowered in PD cybrids, and enhanced
proton leak was apparent [ 100 ]. Mitochondrial membrane potentials
were relatively depolarized [ 99 ]. ATP content was decreased and PD
cybrid cell lines released more LDH [ 99 ]. PD cybrids are more sus-
ceptible to MPP + induced cell death [ 15 , 100 ]. The ultrastructure of
mitochondria is altered and PD cybrids develop synuclein aggregation
indicative of the Lewy bodies observed in the substantia nigra of PD
subjects [ 78 , 108 –110 ]. 
One study isolated clones from PD cybrids which developed Lewy
Bodies, leading to the subcloning of three PD cybrid cell lines [ 110 ].
This approach yielded inconsistent results, as each subcloned PD cy-
brid exhibited different phenotypes. For example, in one clone mito-
chondrial respiration was decreased, in the second clone mitochon-
drial respiration was increased, while in the third clone mitochondrial
respiration went unchanged. However, the data did correspond to thenucleoid content of each clone.  A study of PD cybrids generated on the HeLa cervical carcinoma
ρ0 nuclear background did not ﬁnd any reduction in Complex I ac-
tivity, n = 10 [ 111 ]. It is important to note this study, and it is fair
to assume data obtained from it are accurate. However, the results
from this study have little bearing on the numerous SH-SY5Y and
A549 ρ0 based PD cybrid studies, which have elucidated biochemical
differences between control and PD cybrid cell lines. 
In 1997, Davis et al. reported that, as a group, cybrid cell lines gen-
erated from AD subjects had a lower Complex IV activity than cybrid
cell lines generated from a demographically matched group of control
subjects [ 112 ]. This report was subsequently retracted due to an inter-
pretive error involving non-cybrid data that this manuscript also con-
tained [ 113 ]. The cybrids in this study were generated on an SH-SY5Y
neuroblastoma ρ0 nuclear background. Complex IV Vmax measure-
ments were completed using post-nuclear, mitochondrial enriched
fractions from AD 45 and 20 control cybrid cell lines. The AD cybrid
cell lines had a 20% reduction in Complex IV activity when compared
to the control subjects. Complex I Vmax was equivalent between the
two groups, suggesting that mitochondrial repopulation was compa-
rable. 
These initial AD cybrid data were recapitulated in subsequent
studies. In AD 76 and 111 control cybrid lines also generated against
an SH-SY5Y nuclear background, a 15% reduction in AD cybrid Com-
plex IV activity was observed [ 114 ]. Smaller AD cybrid studies that
used the SH-SY5Y nuclear background have also reported reduced
Complex IV activity [ 107 , 115 –117 ]. Two separate studies using the
NT2 ρ0 cell line to generate AD cybrids also found decreased Complex
IV activity. The ﬁrst study compared AD 15 cybrid lines to 9 control
cybrid lines, and reported a 16% decrease in Complex IV activity [ 23 ].
The second study compared AD 6 cybrid lines to 5 control cybrid lines,
and reported a 22% decrease in Complex IV activity [ 118 ]. 
Cybrids generated from AD patients on both the SH-SY5Y and NT2
nuclear background show biochemical and molecular changes. In-
creased ROS production was demonstrated using ﬂuorescence-based
peroxide measurements [ 23 , 112 , 118 ]. AD cybrids generated on the
NT2 nuclear background displayed increased antioxidant enzyme ac-
tivities, protein carbonyl markers, and lipid peroxidation markers
[ 23 , 118 ]. AD cybrids on both the NT2 and SH-SY5Y nuclear back-
grounds showed activation of MAPK, Akt, and NFkB with increased
caspase-3 activation and cytochrome c cytoplasmic levels [ 118 –121 ].
These ﬁndings are consistent with pathways associated with cell
death and stress responses. AD cybrids generated on the SH-SY5Y
nuclear background had decreased basal heat shock factor I (HSFI)
binding activity, increased phosphoinositide signaling, and low AP1
binding [ 122 , 123 ]. 
Decreased ATP levels (NT2 and SH-SY5Y AD cybrids), reduced mi-
tochondrial movement in neurites (SH-SY5Y AD cybrids), reduced
mitochondrial calcium (SH-SY5Y AD cybrids), reduced mitochondrial
membrane potential (both SH-SY5Y and NT2 AD cybrids), and reduced
mitochondrial “ﬂickering” (SH-SY5Y AD cybrids) have been demon-
strated [ 115 , 117 –119 , 124 –126 ]. AD cybrids generated on the NT2
nuclear background were more susceptible to cell death induced by
β-amyloid exposure [ 118 ]. Mitochondrial ultrastructure is affected in
SH-SY5Y AD cybrid cell lines, and over time increased mitochondrial
proliferation is observed [ 108 , 116 ]. Finally, both intracellular and ex-
tracellular β-amyloid levels were increased in SH-SY5Y AD cybrid cell
lines [ 119 ]. Dense extracellular aggregates which stained positive for
A β1–40 and A β1–42 were also observed in the same study. 
A recently published, detailed examination of AD cybrid cell lines
also reported bioenergetic changes. In this study, 8 AD, 7 mild-
cognitive impairment (MCI, frequently a precursor AD state), and 7
age-matched control cybrid cell lines were generated using platelets
from human subjects and the SH-SY5Y ρ0 nuclear background [ 127 ].
Complex IV activity was signiﬁcantly decreased when normalized to
cytochrome oxidase subunit 4 isoform 1 (COX4I1) protein in the AD
group. Both the MCI and AD cybrids displayed less glycolytic activity,
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 hile the MCI cybrids had decreased basal mitochondrial oxygen con- 
umption and the AD cybrids showed an increased respiratory leak 
ate. Both AD and MCI cybrid cell lines had decreased NAD + / NADH 
atios and the AD cybrids showed increased ADP / ATP ratios. Expres- 
ion of proteins involved in mitochondrial biogenesis and bioener- 
etic ﬂuxes were found to be altered. In both the MCI and AD cybrid 
ell lines, HIF1 α protein was decreased, while its mRNA levels were 
levated. In contrast, PGC1- α expression was reduced in both MCI 
nd AD cybrids. Sirt1 cellular localization was altered, and phospho- 
ylated Sirt1 protein was decreased in AD cybrids. The AD cybrid 
ell lines displayed upregulated expression of phosphorylated AMPK, 
hosphorylated p38, Bax, DRP1, TFAM, cytochrome c, and Complex 
V subunits, and mtDNA levels were increased. mTOR expression was 
educed and phosphorylated DRP1 levels were decreased in the AD 
ybrid cell lines. Overall, bioenergetic ﬂuxes, mitochondrial mass, mi- 
ochondrial morphology dynamics, and cell signaling pathways were 
ltered in the MCI and AD cybrid cell lines. 
An additional study independently examined the same set of AD 
nd control cybrid cell lines [ 128 ]. For the AD cybrid cell lines, a re- 
uction in Complex I, Complex III, and Complex IV activities, as well 
s reduced ATP levels, was reported. ROS production, phosphorylated 
RK, and mitochondrial DLP-1 levels were also increased in AD cy- 
rids. Mitochondrial density and length were decreased. 
A separate study generated AD, MCI, and age-matched control 
ybrid cell lines from human platelets and the NT2 ρ0 nuclear back- 
round [ 117 ]. It was found that both AD and MCI cybrid cell lines had 
ecreased Complex IV activity and mitochondrial membrane poten- 
ial. Increased lipid peroxidation, superoxide production, and protein 
arbonyls were observed in both AD and MCI cybrids. 
One published study of AD cybrids generated on the HeLa nuclear 
ackground is notable for not detecting differences between AD and 
ontrol cybrid line Complex IV activities [ 44 ]. Results from this study 
re confounded by the fact that mtDNA transfer from platelet, ﬁbrob- 
ast, and synaptosomes were attempted, and the sources of mtDNA 
ere not matched between AD and control cybrid cell lines. When 
D and control cybrids generated from platelet mtDNA transfer are 
ompared, data from only three cell lines from each group were pro- 
ided. It is reasonable to take into account this study ’ s small sample 
ize when considering its conclusions. Regardless, even if this report ’ s 
reliminary ﬁndings were to be conﬁrmed in an adequately powered 
eLa-based cybrid study, the relevance of this to the numerous posi- 
ive SH-SY5Y and NT2-based AD cybrid studies would be unclear. 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease 
hat has autosomal dominant and sporadic etiology. Sporadic ALS ac- 
ounts for approximately 90% of ALS cases and has a later age of onset. 
ased on the idea that mtDNA could act as a late onset, sporadic neu- 
odegenerative disease risk factor, the cybrid model was used to study 
tDNA in ALS [ 129 , 130 ]. Platelets from ALS patients were used as the 
tDNA donor and SH-SY5Y neuroblastoma ρ0 cells provided the nu- 
lear background. Eleven ALS cybrid cell lines and 12 age-matched 
ontrol cybrid cell lines were generated. Relative to the control cy- 
rid lines, post-nuclear mitochondrial enriched fractions from the ALS 
ybrid lines displayed trends for reductions in Complex III and Com- 
lex IV activities, and a statistically signiﬁcant reduction in Complex 
 activity [ 131 ]. A subsequent study, interestingly, reported reduced 
omplex I activity in muscle tissue from ALS patients [ 132 ]. Although 
OS production in the form of cytoplasmic peroxide levels was not 
ncreased in ALS cybrids, an increase in antioxidant enzyme activi- 
ies was apparent [ 129 ]. ALS cybrid mitochondria also demonstrated 
educed mitochondrial calcium concentrations. 
A second ALS cybrid study used osteosarcoma ρ0 cells and 
latelets as the mitochondrial donor source [ 133 ]. This study gen- 
rated 13 ALS cybrids and 10 control cybrids. While no difference in 
itochondrial respiration was reported, this study did not directly 
ssay the Complex I Vmax (the parameter demonstrated to be differ- 
nt in the Swerdlow et al. study [ 129 ]). Similarly, no change in ROS production in the form of cytoplasmic peroxide was noted; antioxi- 
dant enzyme levels were not reported. It is difﬁcult to generalize the 
ﬁndings of these studies because there is a lack of overlap between 
experimental parameters, and cybrids were generated using different 
nuclear backgrounds. 
Another late onset, sporadic neurodegenerative disease in which 
the cybrid model has been used is progressive supranuclear palsy 
(PSP). As early as 1994, PSP subjects were found to have reduced mus- 
cle oxidative metabolism [ 134 ]. In the initial PSP cybrid study, lines 
were generated using the SH-SY5Y nuclear background and platelet 
mitochondria from 15 PSP and 17 age-matched control subjects [ 135 ]. 
Compared to control cybrid lines, in the PSP cybrid lines the Com- 
plex I Vmax was reduced by 12.4%, while Complex IV activities were 
equivalent between the groups. Antioxidant enzyme activities were 
elevated (presumably upregulated) in the PSP cybrid group. Other 
investigators have used the same cybrid lines and have reported re- 
ductions in oxidative respiration, activity of Complexes I + III, and 
ATP levels in the PSP cybrids. Aconitase activity is reduced, suggesting 
increased mitochondrial oxidative stress. Exposure to ETC inhibitors 
also caused greater mitochondrial membrane depolarization in the 
PSP cybrids when compared to control cybrids. Treatment of cybrids 
with a Complex I inhibitor, rotenone, caused a more robust increase in 
PSP cybrid malondialdehyde (MDA) and hydroxynonenal (HNE) pro- 
duction than it did in control cybrid lines. Increased MDA and HNE in 
the PSP lines are consistent with a greater degree of rotenone-induced 
oxidative stress. On the other hand, MDA and HNE differences were 
not observed after treatment with malonate (a Complex II inhibitor) 
or cyanide (a Complex IV inhibitor) [ 136 , 137 ]. 
The cybrid model was used to study Huntington ’ s disease (HD), 
a strictly Mendelian, autosomal dominant neurodegenerative dis- 
ease [ 138 ]. While mitochondrial function is perturbed in HD, thereby 
qualifying it as a mitochondriopathy, based on its genetics there is 
no compelling reason to suspect the presence of functionally mean- 
ingful, disease-speciﬁc mtDNA variations (at least not from the per- 
spective of inherited mtDNA sequence deviations). Consistent with 
this prediction, while direct measurements of HD subject platelets 
show decreased Complex I activity [ 139 ], HD cybrid cell lines do not 
[ 138 , 140 , 141 ]. On the other hand, Fereira et al. did report HD cybrids
showed increased glycolysis, increased ATP production, increased 
peroxide production, and decreased mitochondrial NADH:NAD + ra- 
tios [ 140 , 141 ]. If correct, the presence of a mutant Huntingtin gene 
may, therefore, give rise to somatic yet perpetually-sustained mtDNA 
modiﬁcations. 
Finally, the cybrid model has also been used to study mtDNA con- 
tributions to aging. In an initial study, ﬁbroblast mtDNA was used 
to generate cybrids from 21 individuals on an osteosarcoma nuclear 
background [ 142 ]. The cybrid lines generated from these 21 individ- 
uals were subsequently sub-cloned, ultimately giving rise to a total 
of 356 uniquely expanded cybrid cell lines. Among these lines an in- 
verse correlation between mitochondrial respiration and the age of 
the mtDNA donor was observed; the older the mtDNA donor, the 
lower the respiration capacity of the resulting cybrid line. In con- 
trast to this, though, a separate, much smaller study using HeLa ρ0 
cells as the nuclear background did not report correlations between 
mtDNA donor age and respiration [ 143 ]. In this negative study, two 
cybrid cells lines were generated. In one line, mtDNA was obtained 
from ﬁbroblasts from a 97-year old, and in the other mtDNA was 
obtained from ﬁbroblasts from a fetus. This study also used a clonal 
approach, and a total of ﬁve clones were analyzed. Complex IV activity 
constituted the experimental endpoint, and among these ﬁve clones 
comparable Complex IV activities were observed. 
Aging cybrid clones were also generated on an osteosarcoma nu- 
clear background from a 100 year-old donor bearing a T414G mu- 
tation. This particular mutation, which is quantitatively associated 
with aging, is located within the mtDNA control region [ 144 ]. No 
differences in oxygen consumption or ETC activities were observed. 
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 However, two different mutations in the 16S rRNA gene (T1843C
and A1940G) did associate with reduced oxygen consumption and
reduced ETC activities. Lastly, another study that used mouse mus-
cle and synaptosomes to generate cybrid cell lines on a mouse LL /
2-m21 nuclear background [ 27 ] found differences in cybrid lines de-
rived from young and old mtDNA donors. When muscle cytoplasts
were used, cybrids containing mtDNA from the old mice showed de-
creased Complex I and Complex III activities, less ATP production,
and reduced oxygen consumption (but no change in Complex IV ac-
tivity). When synaptosomes were used, cybrids containing mtDNA
form the old mice showed decreased Complex I activity and lowered
ATP levels. 
Methodological considerations 
It is necessary to clarify the point that cybrid methodology varies
signiﬁcantly between individual studies, because these methodolog-
ical variations may potentially account for and / or contribute to con-
ﬂicting ﬁndings. This section discusses these methodological dispar-
ities. 
Overall, the nuclear background of the ρ0 cell line used to gen-
erate cybrid cell lines inﬂuences study outcomes [ 50 , 59 , 71 , 145 , 146 ].
This ﬁnding is not surprising because mitochondrial physiology varies
among tissue types and nuclear DNA largely determines these vari-
ations [ 147 , 148 ]. There is no guarantee that mitochondria obtained
from a common source will similarly function within the context of
different nuclear backgrounds, or that mitochondria obtained from
different sources will consistently function in similar patterns when
expressed within the context of different nuclear backgrounds. 
The majority of ρ0 cell lines generated for use in cybrid models are
tumor cell lines. Tumor cell lines exhibit aneuploidy, and therefore do
not contain a normal chromosome complement. Thus, pieces of chro-
mosomes may be missing or translocated, or additional chromosomes
may be present. Aneuploidy varies signiﬁcantly between different ρ0
cell lines [ 149 –153 ]. While it has not been resolved exactly how aneu-
ploidy impacts mitochondrial function, it could potentially affect nu-
clear DNA-mtDNA ETC subunit stoichiometry. This could cause some
ρ0 cell lines to become more or less sensitive in measurements of
mtDNA genotype–phenotype correlations. Moreover, it is important
to consider that these tumor cells lines are anaerobic at baseline.
Whether or not the aerobic versus anaerobic nature of the host cell
inﬂuences mtDNA genotype–phenotype correlations should be taken
into account. Data regarding this are limited, yet it seems reasonable
to assume cybrid models using ρ0 cell lines derived from more aer-
obic tumor lines may yield inconsistent results when compared with
cybrid studies in which ρ0 cells derive from more anaerobic tumor
lines. 
The majority of cybrid studies have utilized parental cell lines
depleted of mtDNA by exposure to EtBr. However, new techniques
for depleting mtDNA are becoming commercially available. Therefore,
in future cybrid studies it will be imperative to take into account the
method by which the parental cell lines were depleted of mtDNA. The
source of the mtDNA donation, pre-fusion handling of the mtDNA-
donating material, the post-fusion selection process, and variability
in cell culture methods can all potentially inﬂuence ﬁndings. Finally,
assay methodology, assay selection and sample sizes are all potential
variables that need to be considered. 
Reported ﬁndings using the cybrid model were obtained from
studies that used isolated cybrid clones and mixed populations of cy-
brid clones. When a particular assessment requires a homogeneous
population of cybrid cells, the preparation of clonal cybrids is a more
appropriate choice. Examples of such studies include those exam-
ining heteroplasmy-threshold relationships of known mtDNA mu-
tations. When cybrids are used to screen for functionally relevant
mtDNA differences between mtDNA from different mtDNA donors,or when individually expanded clones from a cybrid line are bio-
chemically assayed, the mean value obtained from the independent
assay approximates the value obtained when the same cybrid is as-
sayed using a mixed culture[ 114 ]. In conclusion, when using the cy-
brid model to screen for mtDNA genotype–biochemical phenotype
correlations from unsequenced mtDNA, the use of mixed cybrid pop-
ulations would seem to be the more logical approach. 
The “best” endpoint to show functional differences in mtDNA-
related cybrid lines is unclear and not universal. However, data sug-
gests that radical production is a useful biochemical measure [ 154 ].
In clinical manifestations associated with oxidative stress, the cybrid
model can aid in addressing the origin of free radical generation. If cy-
brid cell lines expressing mtDNA from a group of subjects perpetuate
oxidative stress, this suggests mitochondria, and very likely mtDNA,
contribute to that oxidative stress. 
2. Conclusions 
Data generated using cybrid models have enabled investigators
to address questions related to mtDNA-induced mitochondrial biol-
ogy. Furthermore, cybrid studies have provided important insight into
how altered mitochondrial function inﬂuences cell physiology. Future
investigators should ﬁnd the cybrid model useful when interrogating
nuclear–mitochondrial interactions. For studies investigating mtDNA
heteroplasmy-threshold analysis, the cybrid model provides straight-
forward data that appropriately illustrate fundamental mitochondrial
genetic principles. However, generalizing data to non-artiﬁcial bi-
ological models must proceed with caution, because critical differ-
ences exist between experimentally generated cybrid cell lines and
the actual systems they serve to model. 
Functional assessments of mitochondria with un-sequenced
mtDNA show mitochondria from different sources are functionally
unique. For several sporadic neurodegenerative diseases that do not
show Mendelian inheritance, and where mitochondrial dysfunction
occurs, mitochondrial transfer from individuals afﬂicted with those
diseases can generate cybrid cell lines which recapitulate and per-
petuate the same biochemical defects. The most straightforward in-
terpretation for these ﬁndings is that mtDNA at least partly drives
functional alterations observed in both the disease state and in cybrid
cell lines prepared via the transfer of mitochondria obtained from the
human subjects. While this interpretation has not been conclusively
conﬁrmed, data to date do not support an alternative explanation. 
While cybrids remain a valuable technique and will continue
to inform mtDNA-oriented studies, it is worth noting that animal-
based models are also increasingly being used to elucidate mtDNA
genotype–phenotype correlations. In one example, female progeny
were backcrossed repeatedly with their original paternal strain [ 155 ].
Since mtDNA is maternally inherited, the mouse line that resulted
was one in which the nuclear background was almost exclusively
from the paternal strain, while the mtDNA was entirely from the
maternal strain. These mouse studies, which use the same nuclear
background with varying mtDNA show differences in oxidative phos-
phorylation phenotypes, which may be relevant to multifactorial dis-
eases [ 63 , 156 –158 ]. Other mouse models include those that express
mutated versions of genes used in mtDNA replication and mainte-
nance [ 159 –161 ]. Mitochondrial DNA transgenic mice have also been
generated, and review articles describing these advances have been
published [ 162 –165 ]. Finally, recent advances that allow for the trans-
fer of mitochondria between different mouse strains will very likely
advance our understanding of nuclear DNA–mtDNA functional rela-
tionships, as well as the impact of mtDNA variation on cell physiology
[ 166 ]. 
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